Latest Headlines
-
Precision NanoSystems And Aurora Vaccines Join Forces To Accelerate The Development Of Vaccine Candidate For Hepatitis C Virus
6/23/2023
Global leader in non-viral delivery of genomic medicines, Precision NanoSystems (PNI), entered into a strategic collaboration agreement with Aurora Vaccines to accelerate the development and manufacture of its Hepatitis C vaccine candidate. PNI will share its expertise in the development of the RNA payload platform and its proprietary lipid nanoparticle (LNP) platforms to help bring Aurora’s RNA-LNP vaccine candidate for the prevention of Hepatitis C virus (HCV) infection to a Phase I clinical trial.
-
Parker Strengthens Bioscience Filtration Manufacturing Operations At Birtley, UK Site
6/22/2023
Parker Hannifin, the global leader in motion and control technologies, will make a multimillion-dollar investment into its Bioscience Filtration site in Birtley, UK.
-
Nanoform, Celanese Demonstrate Enhanced Drug Delivery
6/15/2023
Nanoform Finland Plc and Celanese Corporation provide an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery.
-
Single Use Support Further Expands Into US Market
6/14/2023
Single Use Support, leading provider of fluid management and freeze-thaw logistic solutions for the biopharmaceutical industry, is excited to announce its further expansion into the United States market.
-
Qosina And Carolina Components Partner To Promote FlowLinX Bioprocessing Components
6/8/2023
Qosina, a global supplier of OEM single-use components to the medical and biopharmaceutical industries, is happy to announce its partnership with Carolina Components Group, a leading supplier of primary and support production materials for the pharmaceutical and biotech manufacturing industries.
-
Presentations, Roundtable Discussions, And Interviews: ISCT Paris 2023
6/8/2023
As a CDMO specializing in cell therapy manufacturing, BioCentriq was eager to participate in this event focused on cell and gene therapy translation, which takes an integrative approach across all stakeholders to tackle key topics ranging from translational research and preclinical development through clinical trials, regulatory approvals, commercialization, and the ultimate goal of patient access.
-
Purolite Grows Bioprocessing Production Capacity With New U.S. Manufacturing Facility
6/7/2023
Ecolab Inc., the world’s water, hygiene and infection prevention company, today announced a further expansion of its Purolite business with the addition of a new biologics resin manufacturing facility in Landenberg, Pennsylvania. Construction plans for the new facility are underway and will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
-
BioCentriq Hosts Cohort From Bpeace Pharma Maximizer Program
6/7/2023
BioCentriq had the great pleasure of hosting ten leaders from five different Salvadoran businesses who are participants in Bpeace’s Pharma Maximizer program.
-
BioCentriq, Kytopen Expand Partnership To Optimize CGT Manufacturing
6/6/2023
Learn how the extended partnership will expand therapeutic developers’ access to a leading non-viral cell engineering method by combining BioCentriq’s process development expertise with Kytopen’s Flowfect Discover™ platform.
-
Advanced Therapy Platform Helps Biotechs Reach Patients In Record Time
6/1/2023
Discover the platform designed to help early-stage biotech companies get to patients faster by using pre-existing processes and documentation, already qualified equipment, facilities and people, and other knowledge assets.